aTyr Pharma (NASDAQ:LIFE) released its quarterly earnings results on Wednesday. The biotechnology company reported ($1.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.74) by $0.94, Morningstar.com reports. The business had revenue of $0.09 million during the quarter.
Shares of NASDAQ LIFE traded up $0.07 during midday trading on Thursday, reaching $2.87. The company’s stock had a trading volume of 905 shares, compared to its average volume of 159,297. The company has a current ratio of 4.00, a quick ratio of 4.00 and a debt-to-equity ratio of 0.31. aTyr Pharma has a fifty-two week low of $2.80 and a fifty-two week high of $12.32. The stock’s 50 day moving average price is $3.67.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wedbush Securities Inc. increased its stake in aTyr Pharma by 158.7% in the second quarter. Wedbush Securities Inc. now owns 67,270 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 41,271 shares during the last quarter. Vanguard Group Inc. increased its stake in aTyr Pharma by 1.9% in the second quarter. Vanguard Group Inc. now owns 1,779,024 shares of the biotechnology company’s stock valued at $652,000 after acquiring an additional 33,702 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in aTyr Pharma by 19.8% in the second quarter. Renaissance Technologies LLC now owns 1,845,873 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 305,314 shares during the last quarter.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Read More: What is meant by a buy rating?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.